Delisting risk
Polyrizon (PLRZ)
Develops NASARIX and intranasal hydrogel drug-delivery platforms.
$12.50
Pre-market−0.25 (−1.96%)
At close$12.75(−11.21%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions2 holders · as of Sep 30, 2025 | 0.18% | 2.1K ADS | |
| Otherremainder | 99.82% | 1.12M ADS |
1.12M ADS as of Aug 21, 2026 · institutions as of Sep 30, 2025 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Institutions13F, as of Sep 30, 2025
2 holders · 12.4K shares · 0 new positions · 0 increased · 2 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| UBS Group AG | 12.3K | 1.10% | −17.3K | Nov 13, 2025 |
| Citigroup Inc | 115 | 0.01% | −392 | Nov 10, 2025 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| MMCAP International Inc. SPC | 7.30% | 136.5K | 13G | Apr 28, 2026 ↗ |
| Tomer Izraeli | 5.46% | 13G | Mar 5, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 31, 2026 | Oz Adlerdirector | Sale | 3,292 | $12.05 | 19,850 |
| Mar 31, 2026 | Liron Carmeldirector | Sale | 942 | $12.36 | 3,127 |
| Mar 31, 2026 | Tomer Izraelidirector, officer: Chief Executive Officer | Sale | 500 | $11.85 | 31,512 |
| Mar 30, 2026 | Tidhar Turgemandirector, officer: Chief Technology Officer | Sale | 2,917 | $10.90 | 17,518 |
| Mar 30, 2026 | Tomer Izraelidirector, officer: Chief Executive Officer | Sale | 3,900 | $10.90 | 32,012 |
| Mar 30, 2026 | Liron Carmeldirector | Sale | 100 | $11.00 | 4,069 |
CongressHouse and Senate disclosures
Not reported.